BTIG Maintains Buy on Insulet, Lowers Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Marie Thibault maintains a Buy rating on Insulet (NASDAQ:PODD) but lowers the price target from $270 to $250.

August 09, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BTIG analyst Marie Thibault maintains a Buy rating on Insulet but lowers the price target from $270 to $250.
The Buy rating suggests continued confidence in Insulet's long-term prospects, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100